282 related articles for article (PubMed ID: 25573527)
1. Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Katayama K; Misawa S; Sato Y; Sobue G; Yabe I; Watanabe O; Nishizawa M; Kusunoki S; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
BMJ Open; 2015 Jan; 5(1):e007330. PubMed ID: 25573527
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Misawa S; Sato Y; Katayama K; Nagashima K; Aoyagi R; Sekiguchi Y; Sobue G; Koike H; Yabe I; Sasaki H; Watanabe O; Takashima H; Nishizawa M; Kawachi I; Kusunoki S; Mitsui Y; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
Lancet Neurol; 2016 Oct; 15(11):1129-37. PubMed ID: 27496680
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial.
Suichi T; Misawa S; Nagashima K; Sato Y; Iwai Y; Katayama K; Sekiguchi Y; Shibuya K; Amino H; Suzuki YI; Tsuneyama A; Nakamura K; Kuwabara S
Intern Med; 2020 May; 59(9):1149-1153. PubMed ID: 32009091
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study.
Misawa S; Sato Y; Katayama K; Hanaoka H; Sawai S; Beppu M; Nomura F; Shibuya K; Sekiguchi Y; Iwai Y; Watanabe K; Amino H; Ohwada C; Takeuchi M; Sakaida E; Nakaseko C; Kuwabara S
BMJ Open; 2015 Nov; 5(11):e009157. PubMed ID: 26560063
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome.
Kuwabara S; Misawa S; Kanai K; Sawai S; Hattori T; Nishimura M; Nakaseko C
J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1255-7. PubMed ID: 18469028
[TBL] [Abstract][Full Text] [Related]
6. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R; Hamada H; Sato Y; Suzuki H; Onouchi Y; Ebata R; Nagashima K; Terauchi M; Terai M; Hanaoka H; Hata A;
BMJ Open; 2015 Dec; 5(12):e009562. PubMed ID: 26628527
[TBL] [Abstract][Full Text] [Related]
7. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome.
Li J; Huang XF; Cai QQ; Wang C; Cai H; Zhao H; Zhang L; Cao XX; Gale RP; Zhou DB
Am J Hematol; 2018 Jun; 93(6):803-809. PubMed ID: 29603764
[TBL] [Abstract][Full Text] [Related]
8. [Clinical observation of thalidomide combined with VAD regimen for treatment of osteosclerotic myeloma (POEMS syndrome)].
Zhou JW; Sun H; Gan SL; Liu YF; Sun L; Wan DM; Meng XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):348-51. PubMed ID: 22541096
[TBL] [Abstract][Full Text] [Related]
9. Correlation of changes in serum level of VEGF and peripapillary retinal thickness in patients with POEMS syndrome.
Yokouchi H; Baba T; Misawa S; Oshitari T; Kuwabara S; Yamamoto S
Br J Ophthalmol; 2020 Jan; 104(1):33-38. PubMed ID: 30914422
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy.
He T; Zhao A; Zhao H; Cai H; Feng J; Zhang L; Cao X; Zhou D; Li J
Ann Hematol; 2019 Mar; 98(3):735-743. PubMed ID: 30612232
[TBL] [Abstract][Full Text] [Related]
11. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Briani C; Manara R; Lessi F; Citton V; Zambello R; Adami F
Am J Hematol; 2012 May; 87(5):539-41. PubMed ID: 22389216
[TBL] [Abstract][Full Text] [Related]
12. Multiple angiogenetic factors are upregulated in POEMS syndrome.
Yamada Y; Sawai S; Misawa S; Kanai K; Shibuya K; Mori M; Moriya J; Sogawa K; Yamamoto H; Beppu M; Taniguchi J; Nakaseko C; Nomura F; Kuwabara S
Ann Hematol; 2013 Jan; 92(2):245-8. PubMed ID: 23053181
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of POEMS syndrome with lenalidomide and dexamethasone].
Goto A; Iyama S; Sugama Y; Yoshida M; Ibata S; Tatekoshi A; Fujita C; Kikuchi S; Ikeda H; Murase K; Takada K; Kato J; Kobune M
Rinsho Ketsueki; 2019; 60(4):308-313. PubMed ID: 31068561
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
Wang X; Ye S; Xiong C; Gao J; Xiao C; Xing X
Jpn J Clin Oncol; 2011 Oct; 41(10):1221-4. PubMed ID: 21890654
[TBL] [Abstract][Full Text] [Related]
15. Intractable ascites, changes in serum vascular endothelial growth factor levels and thalidomide treatment in POEMS syndrome.
Wu KL; Chen HW; Lin SH; Chen JS
Am J Med Sci; 2014 Jun; 347(6):510-2. PubMed ID: 24781436
[No Abstract] [Full Text] [Related]
16. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Furuta S; Sugiyama T; Umibe T; Kaneko Y; Amano K; Kurasawa K; Nakagomi D; Hiraguri M; Hanaoka H; Sato Y; Ikeda K; Nakajima H;
BMJ Open; 2017 Dec; 7(12):e018748. PubMed ID: 29247107
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial.
Nozza A; Terenghi F; Gallia F; Adami F; Briani C; Merlini G; Giordano L; Santoro A; Nobile-Orazio E
Br J Haematol; 2017 Dec; 179(5):748-755. PubMed ID: 29048107
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
19. Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation.
Imai N; Taguchi J; Yagi N; Konishi T; Serizawa M; Kobari M
Neuromuscul Disord; 2009 May; 19(5):363-5. PubMed ID: 19269178
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
